Are you ready to amplify your academic presence and connect with a global network of researchers? Join the Scholar Indexing Society and elevate your research to new heights!
Combination Therapy for Chronic HBV Infection
Article Number: SIS812354AI050825
5th August, 2025
Author(s):
Harry L.A. Janssen, Milan J. Sonneveld
Abstract:
This editorial contextualizes new trial findings on xalnesiran, an siRNA targeting HBV surface antigen administered alone or with immunomodulators (pegylated interferon alfa-2a or ruzotolimod) in patients on nucleos(t)ide analogues. Combination therapy showed greater rates of hepatitis B surface antigen (HBsAg) clearance, with up to 23% achieving off-treatment functional cure. However, relapses occurred post-therapy, raising questions about treatment durability and endpoint timing. The authors emphasize functional cure as the aspirational goal in HBV management, linked to reduced hepatocellular carcinoma risk. The piece explores immunologic mechanisms, drug synergy, and challenges in targeting patients with high HBsAg levels, those at greatest risk but hardest to cure. Future directions include stratified treatment regimens and validated immune restoration models.